Abstract:Exploring alternative biomedical use of traditional drugs in different disease models is highly important as it can reduce the cost of drug development and overcome several critical issues of traditional chemodrugs such as low chemotherapeutic efficiency, severe side effect, and drug resistance. Disulfiram (DSF), a clinically approved alcohol-aversion drug, was recently demonstrated to feature tumor-growth suppression effect along with the co-administration of Cu2+ species, but direct Cu2+ administration mode might cause severe toxicity originating from low Cu2+ accumulation into the tumor and nonspecific Cu2+ distribution-induced cytotoxicity. Based on the intriguing drug-delivery performance of nanoscale metal-organic frameworks (MOFs), we herein construct HKUST nMOFs as the Cu2+ self-supplying nanocarriers for efficient delivery of the DSF drug. The mildly acidic condition of tumor microenvironment initially triggered the release of Cu ions from HKUST nMOFs, which further reacted with the encapsulated DSF to form toxic Cu(DDTC)2 (activation) for tumor chemotherapy. Especially, during the Cu(DDTC)2 complexation, Cu+ species were formed concomitantly, triggering the intratumoral nanocatalytic therapy for the generation of reactive oxygen species to synergistically destroying the tumor cells/tissue. As a result, synergetic tumor-responsive chemotherapy and nanocatalytic therapy are enabled by DSF@HKUST nanodrugs, as demonstrated by the dominant anticancer efficacy with satisfied biocompatibility both in vitro and in vivo. The present work offers a sophisticated strategy for tumor-responsive nontoxic-to-toxic therapeutic with high biocompatibility.

Self-supplying Cu2+ and Oxidative Stress Synergistically Enhanced Disulfiram-Mediated Melanoma Chemotherapy

Self-supplying Cu 2+ and H 2 O 2 synergistically enhancing disulfiram-mediated melanoma chemotherapy

Assessment of electromagnetic radiation exposure of embarked personnel on Romanian naval ships

Nanomedicine-based Disulfiram and Metal Ion Co-Delivery Strategies for Cancer Treatment

Co-delivery of a tumor microenvironment-responsive disulfiram prodrug and CuO2 nanoparticles for efficient cancer treatment

Buffet-style Cu(II) for enhance disulfiram-based cancer therapy

V9302-loaded copper-polyphenol hydrogel for enhancing the anti-tumor effect of disulfiram

Engineering of a double targeting nanoplatform to elevate ROS generation and DSF anticancer activity

Tumor-responsive copper-activated disulfiram for synergetic nanocatalytic tumor therapy

Tumor‐Microenvironment‐Responsive Cerium‐Enriched Copper Nanozyme with O2 Supply And Oxidative Stress Amplification for In Situ Disulfiram Chemotherapy And Chemodynamic Therapy Intensification

[Demonstration of hepatitis-associated antigen (Au-SH): various methodological aspects of immunoprecipitation technics].

Polydopamine-Modified Copper Coordination Mesoporous Silica Nanoparticles Loaded with Disulfiram for Synergistic Chemo-Photothermal Therapy

A Cascade Nanoplatform for the Regulation of the Tumor Microenvironment and Combined Cancer Therapy.

Two birds with one stone: Copper metal-organic framework as a carrier of disulfiram prodrug for cancer therapy

Coordinating effect of ferroptosis and in situ disulfiram toxification for enhanced cancer therapy

Chemotherapeutic trials in psychosis. III. 2-Brom-d-lysergic acid diethylamide (BOL 148).

Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems

A CD44-targeted Cu(ii) delivery 2D nanoplatform for sensitized disulfiram chemotherapy to triple-negative breast cancer

Biodegradable Nanocatalyst with Self-Supplying Fenton-like Ions and H2O2 for Catalytic Cascade-Amplified Tumor Therapy

Active-transporting of charge-reversal Cu(II)-doped mesoporous silica nanoagents for antitumor chemo/chemodynamic therapy

In situ triggering antitumor efficacy of alcohol-abuse drug disulfiram through Cu-based metal-organic framework nanoparticles